# [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

> **NCT06502691** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Washington** · enrollment: 22 (estimated)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Breast Carcinoma

## Interventions

- **OTHER:** Best Practice
- **PROCEDURE:** Biopsy of Breast
- **PROCEDURE:** Computed Tomography
- **OTHER:** Electronic Health Record Review
- **OTHER:** Fludeoxyglucose F-18
- **RADIATION:** Fluorine F 18 Fluorthanatrace
- **DRUG:** Immune Checkpoint Inhibitor
- **DRUG:** Poly (ADP-Ribose) Polymerase Inhibitor
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT06502691
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-26
- **Primary completion:** 2027-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06502691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06502691, "[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06502691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*